The medicine comes before the setting
What do you hope a visit will help with? That is a more useful opening than asking for peptide therapy in general. A clinician is a health professional who can assess a health concern. Ask that person to name the proposed medicine and the reason for it in words you can repeat back.
Picture small building blocks joined into a short string. That is a peptide; its blocks are called amino acids. Those building blocks also make up proteins. Insulin belongs to the peptide group.
Compounding means making a drug for a particular medical need. A drug made under every compounding condition can be lawful despite lacking FDA approval, under rules checked on November 3, 2026. The full agency name behind FDA is Food and Drug Administration. Lawfully compounded drugs form a separate group from FDA-approved products and from unapproved drugs offered outside those legal permissions. Calling something a peptide does not place it in any of those groups.
Source: FDA, Compounding and the FDA: Questions and Answers
Ready-made and made for a particular need
An approved product
The November 3, 2026 check confirms FDA-approved tirzepatide products named Mounjaro and Zepbound. Semaglutide products with approval include Ozempic and Wegovy.
FDA reviews specific medicine products. Approval concerns a particular product and use, rather than every treatment with a similar name.
Ask for the full name and form of the proposed medicine. Do not let an offer stay at the level of a family name.
A compounded preparation
A physician or pharmacist, or a facility registered for this work, prepares a drug for a particular need in compounding. The process differs from manufacturing a finished approved product.
FDA information checked November 3, 2026 says compounded drugs receive no FDA approval and no advance FDA check of their quality, safety or effectiveness.
In FDA’s description, a patient may need compounding when a ready-made approved drug falls short of their medical need.
Which of your needs would the approved product leave unmet? Ask the clinician to spell it out.
A research label leaves a different question
Research is work done to learn about a substance. It is not the same thing as receiving medical care. An online mention of a study may be interesting, but it does not tell you what a clinician is proposing for you.
In its position checked November 3, 2026, FDA says research-labeled products marketed for human use can still be unapproved drugs, despite the research wording.
An NDC identifies a drug product in FDA’s directory; the letters mean National Drug Code. FDA says that identifier does not demonstrate product approval.
Source: FDA, National Drug Code Directory
Would the person discussing treatment show you the product’s approval record, or only a code and a list of papers? Ask them to explain the difference. Keep the answer with the full medicine name so that separate claims do not blur into a single promise.
What to carry into a visit
Write your goal as a concern rather than a demand for a named product. Name the concern in your own words, including what you want the visit to address. Add the medicine names you have seen, even if you cannot pronounce them. It is fine to ask for those names to be written down.
Then ask about the other options for that concern, including the option of no medicine. Ask what information the clinician needs before deciding. A useful conversation makes room for your own questions, rather than treating the product choice as already settled.
Keep the visit format separate from this discussion. A local office and a remote service can be compared on how they assess the concern and explain the proposed care. The place where the conversation happens does not answer what the medicine is.